The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology.

Clinical utility describes the benefits of each laboratory test for that patient. Many stakeholders have adopted narrow definitions for the clinical utility of molecular testing as applied to targeted pharmacotherapy in oncology, regardless of the population tested or the purpose of the testing. This definition does not address all of the important applications of molecular diagnostic testing. Definitions consistent with a patient-centered approach emphasize and recognize that a clinical test result's utility depends on the context in which it is used and are particularly relevant to molecular diagnostic testing because of the nature of the information they provide. Debates surrounding levels and types of evidence needed to properly evaluate the clinical value of molecular diagnostics are increasingly important because the growing body of knowledge, stemming from the increase of genomic medicine, provides many new opportunities for molecular testing to improve health care. We address the challenges in defining the clinical utility of molecular diagnostics for inherited diseases or cancer and provide assessment recommendations. Starting with a modified analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications model for addressing clinical utility of molecular diagnostics with a variety of testing purposes, we recommend promotion of patient-centered definitions of clinical utility that appropriately recognize the valuable contribution of molecular diagnostic testing to improve patient care.

[1]  V. Miller,et al.  Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein , 2014, Journal of Hematology & Oncology.

[2]  J. Lentz,et al.  Usher Syndrome Type 2 , 2016, Definitions.

[3]  A. Marchevsky,et al.  Evidence-based pathology: systematic literature reviews as the basis for guidelines and best practices. , 2015, Archives of Pathology & Laboratory Medicine.

[4]  Ashish Choudhary,et al.  Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. , 2013, The Journal of molecular diagnostics : JMD.

[5]  E. Alexander,et al.  Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. , 2014, Thyroid : official journal of the American Thyroid Association.

[6]  D. Lipson,et al.  Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary , 2014, Case Reports in Oncology.

[7]  H. Elphick,et al.  Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis , 2013, Drug design, development and therapy.

[8]  Mary B. Daly,et al.  BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer , 2013 .

[9]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[10]  R. Schilsky,et al.  Molecular markers to individualize adjuvant therapy for colon cancer , 2010, Nature Reviews Clinical Oncology.

[11]  Suk-Kyeong Kim,et al.  RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma , 2015, Clinical endocrinology.

[12]  P. Shannon,et al.  Exome sequencing identifies the cause of a Mendelian disorder , 2009, Nature Genetics.

[13]  P. Stephens,et al.  Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. , 2014, Clinical breast cancer.

[14]  W. Burke,et al.  Debating Clinical Utility , 2010, Public Health Genomics.

[15]  Judy H. Cho,et al.  Expanded genetic screening panel for the Ashkenazi Jewish population , 2015, Genetics in Medicine.

[16]  P. Kowey,et al.  Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients? , 2014, World journal of cardiology.

[17]  G. Lyman,et al.  Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology , 2015, Genetics in Medicine.

[18]  Steven J. M. Jones,et al.  Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors , 2010, Genome Biology.

[19]  Mary Brophy,et al.  Million Veteran Program: A mega-biobank to study genetic influences on health and disease. , 2016, Journal of clinical epidemiology.

[20]  E. Deeks Ivacaftor: A Review of Its Use in Patients with Cystic Fibrosis , 2013, Drugs.

[21]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[22]  A. Guttmacher,et al.  International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia , 2009, Journal of Medical Genetics.

[23]  Simona Soverini,et al.  BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. , 2011, Blood.

[24]  S. Swerdlow WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[25]  K. Klinger,et al.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening , 2001, Genetics in Medicine.

[26]  David C. Atkins,et al.  Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Austin,et al.  MARFAN SYNDROME , 2018, Cassidy and Allanson's Management of Genetic Syndromes.

[28]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[29]  Ken Chen,et al.  Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. , 2011, JAMA.

[30]  Amy Maxmen,et al.  Exome Sequencing Deciphers Rare Diseases , 2011, Cell.

[31]  A. Chapelle The Incidence of Lynch Syndrome , 2004, Familial Cancer.

[32]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[33]  H. Hakonarson,et al.  Whole-genome DNA/RNA sequencing identifies truncating mutations in RBCK1 in a novel Mendelian disease with neuromuscular and cardiac involvement , 2013, Genome Medicine.

[34]  H. Hakonarson,et al.  Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency. , 2011, American journal of human genetics.

[35]  R. Pai,et al.  Preoperative GNAS and KRAS Testing in the Diagnosis of Pancreatic Mucinous Cysts , 2014, Clinical Cancer Research.

[36]  Rena A. Godfrey,et al.  The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases , 2011, Genetics in Medicine.

[37]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[38]  Elaine Lyon,et al.  The Evolving Role of the Laboratory Professional in the Age of Genome Sequencing: A Vision of the Association for Molecular Pathology. , 2015, The Journal of molecular diagnostics : JMD.

[39]  David B. Matchar,et al.  Chapter 1: Introduction to the Methods Guide for Medical Test Reviews , 2012, Journal of general internal medicine.

[40]  Jonathan S Berg,et al.  Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. , 2015, American journal of human genetics.

[41]  Michael F. Wangler,et al.  De novo truncating mutations in AHDC1 in individuals with syndromic expressive language delay, hypotonia, and sleep apnea. , 2014, American journal of human genetics.

[42]  I. Schmidt-Wolf,et al.  Hairy cell leukemia: short review, today's recommendations and outlook , 2014, Blood Cancer Journal.

[43]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[45]  I. Yang,et al.  Molecular staging for survival prediction of colorectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[47]  Gil McVean,et al.  The 100,000 Genomes Project Protocol , 2017 .

[48]  Alfonso Valencia,et al.  Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment , 2014, Clinical Cancer Research.

[49]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[50]  BlueCross BlueShield Special report: exome sequencing for clinical diagnosis of patients with suspected genetic disorders. , 2013, Technology Evaluation Center Assessment Program. Executive summary.

[51]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[52]  Philipp W. Raess,et al.  The Role of Molecular Pathology in the Diagnosis of Cutaneous Lymphomas , 2012, Pathology research international.

[53]  J. Dungan Association Between Carrier Screening and Incidence of Cystic Fibrosis , 2010 .

[54]  Fabio Mosca,et al.  Prevalence of the Congenital Long-QT Syndrome , 2009, Circulation.

[55]  James C. Mullikin,et al.  Exome sequencing: the sweet spot before whole genomes , 2010, Human molecular genetics.

[56]  M. Greene,et al.  A major step forward for BRCA1/2-related cancer risk management. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Bibbo,et al.  The added value of molecular testing in small pancreatic cysts. , 2010, JOP : Journal of the pancreas.

[58]  M. McDevitt,et al.  Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[59]  A. Tefferi,et al.  Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.

[60]  R. Seethala,et al.  Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next‐generation sequencing assay , 2014, Cancer.

[61]  V. Eysselein,et al.  Fluid genetic analyses predict the biological behavior of pancreatic cysts: three-year experience. , 2014, JOP : Journal of the pancreas.

[62]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[63]  B. Harper Huntington Disease , 2005, Journal of the Royal Society of Medicine.

[64]  Shivang Doshi,et al.  Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis , 2016, The Journal of molecular diagnostics : JMD.

[65]  R. Sullivan,et al.  Resistance to BRAF-targeted therapy in melanoma. , 2013, European journal of cancer.

[66]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[67]  K. Owzar,et al.  Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. , 2005, The New England journal of medicine.

[68]  Darya Chudova,et al.  Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. , 2012, The New England journal of medicine.

[69]  Quantifying the health benefits of genetic tests: A clinical perspective , 2006, Genetics in Medicine.

[70]  J. Fagin,et al.  Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Michael B Atkins,et al.  Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.

[72]  M. HershmanJerome,et al.  Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. , 2014 .

[73]  M. Nikiforova,et al.  New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers , 2013, Clinical Cancer Research.

[74]  G. Giaccone,et al.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, Archives of pathology & laboratory medicine.

[75]  Jeff Shrager,et al.  Rapid learning for precision oncology , 2014, Nature Reviews Clinical Oncology.

[76]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[77]  D. Aisner,et al.  A Suggested Molecular Pathology Curriculum for Residents: A Report of the Association for Molecular Pathology. , 2016, The Journal of molecular diagnostics : JMD.

[78]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[79]  Alexander F. Wilson,et al.  Research in Genomic Medicine the Clinseq Project: Piloting Large-scale Genome Sequencing for Material Supplemental , 2009 .

[80]  Roberta A Pagon,et al.  GeneTests: an online genetic information resource for health care providers. , 2006, Journal of the Medical Library Association : JMLA.

[81]  Jodi B. Segal,et al.  Chapter 3: Choosing the Important Outcomes for a Systematic Review of a Medical Test , 2012, Journal of general internal medicine.

[82]  Nicola D. Roberts,et al.  Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. , 2014, Blood.

[83]  Marc S. Williams,et al.  US system of oversight for genetic testing: a report from the Secretary's Advisory Committee on Genetics, Health and Society. , 2008, Personalized medicine.

[84]  P. Stephens,et al.  Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.